HUTCHMED (China) Limited - American Depositary Shares (HCM)
HCM moved a median of 0.00% 30 minutes after news, and +0.20% by the close. How HCM actually reacts to news — the realized, point-in-time move the market made, measured across 263 labeled events over the last three years with zero look-ahead.
HCM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 255 |
| 30-min | 0.00% | 47% | 261 |
| 60-min | +0.06% | 52% | 262 |
| to close | +0.20% | 52% | 263 |
| Middle 50% of HCM reactions | -0.72% to +0.80% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 263 |
Half of all HUTCHMED (China) Limited - American Depositary Shares news events land between -0.72% and +0.80% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How HCM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 17 | 0.00% | 47% | +0.20% |
| Analyst downgrades | 15 | 0.00% | 47% | -0.18% |
| Rating reiterations | 10 | +0.04% | 60% | -0.13% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how HCM ranks against every other measured name →
That’s how HCM usually reacts — get an email when it moves on news →Email me when HCM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to HCM's baseline. Nothing else.
Recent HCM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K HUTCHMED (China) Ltd For: Sep 28 | SEC filing · Form 6-K | SEC EDGAR | -0.21% | -0.28% | |
| Form 6-K HUTCHMED (China) Ltd For: Sep 29 | SEC filing · Form 6-K | SEC EDGAR | -0.21% | -0.28% | |
| HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer | Press release | GlobeNewswire | -0.21% | -0.28% | |
| HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors | Press release | GlobeNewswire | +0.36% | +1.44% | |
| Form 6-K HUTCHMED (China) Ltd For: Sep 24 | SEC filing · Form 6-K | SEC EDGAR | -0.07% | -0.50% | |
| HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 | Press release | GlobeNewswire | -0.07% | -0.50% | |
| Form 6-K HUTCHMED (China) Ltd For: Sep 03 | SEC filing · Form 6-K | SEC EDGAR | +2.21% | +3.75% | |
| HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy | Press release | GlobeNewswire | +2.21% | +3.75% | |
| Form 6-K HUTCHMED (China) Ltd For: Aug 31 | SEC filing · Form 6-K | SEC EDGAR | -1.13% | -2.57% | |
| HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China | Press release | GlobeNewswire | -1.13% | -2.57% | |
| Form 6-K HUTCHMED (China) Ltd For: Aug 28 | SEC filing · Form 6-K | SEC EDGAR | +0.04% | -0.16% | |
| HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma | Press release | GlobeNewswire | +0.04% | -0.16% | |
| Form 6-K HUTCHMED (China) Ltd For: Aug 18 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.32% | |
| Form 6-K HUTCHMED (China) Ltd For: Aug 17 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.63% | |
| HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® | Press release | GlobeNewswire | +0.00% | -0.63% | |
| Form 6-K HUTCHMED (China) Ltd For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -0.72% | -2.97% | |
| HUTCHMED Reports 2026 Interim Results | Press release | GlobeNewswire | -0.72% | -2.97% | |
| Form 6-K HUTCHMED (China) Ltd For: Jul 02 | SEC filing · Form 6-K | SEC EDGAR | +0.35% | +1.06% | |
| HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification | Press release | GlobeNewswire | +0.35% | +1.06% | |
| Form 6-K HUTCHMED (China) Ltd For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.94% | +1.51% | |
| HUTCHMED to Announce 2026 Half-Year Financial Results | Press release | GlobeNewswire | +0.94% | +1.51% | |
| Form 6-K HUTCHMED (China) Ltd For: Jun 29 | SEC filing · Form 6-K | SEC EDGAR | -0.28% | +1.52% | |
| Form 6-K HUTCHMED (China) Ltd For: Jun 25 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.19% | |
| HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026 | Press release | GlobeNewswire | +0.00% | -0.19% | |
| Form 6-K HUTCHMED (China) Ltd For: Jun 12 | SEC filing · Form 6-K | SEC EDGAR | +2.13% | +1.39% | |
| HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress | Press release | GlobeNewswire | +2.13% | +1.39% | |
| Form S-8 HUTCHMED (China) Ltd | SEC filing · Form S-8 | SEC EDGAR | -1.06% | -2.30% | |
| Form 6-K HUTCHMED (China) Ltd For: Jun 05 | SEC filing · Form 6-K | SEC EDGAR | -2.80% | -1.72% | |
| Form 6-K HUTCHMED (China) Ltd For: May 22 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.08% | |
| Form 6-K HUTCHMED (China) Ltd For: May 21 | SEC filing · Form 6-K | SEC EDGAR | +0.21% | +0.50% | |
| HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma | Press release | GlobeNewswire | +0.21% | +0.50% | |
| HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | +0.00% | -0.08% | |
| Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma | Press release | PR Newswire | +0.21% | +0.50% | |
| Form 6-K HUTCHMED (China) Ltd For: May 12 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.55% | |
| Form 6-K HUTCHMED (China) Ltd For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | +0.22% | +0.52% | |
| Form 6-K HUTCHMED (China) Ltd For: Apr 29 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.26% | |
| HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Press release | GlobeNewswire | +0.00% | -1.26% | |
| Form 6-K HUTCHMED (China) Ltd For: Apr 09 | SEC filing · Form 6-K | SEC EDGAR | +0.40% | +1.20% | |
| HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 | Press release | GlobeNewswire | +0.40% | +1.20% | |
| Form 6-K HUTCHMED (China) Ltd For: Mar 23 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.71% | |
| HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China | Press release | GlobeNewswire | +0.00% | -0.71% | |
| Form 6-K HUTCHMED (China) Ltd For: Mar 16 | SEC filing · Form 6-K | SEC EDGAR | +1.14% | +2.00% | |
| Form 6-K HUTCHMED (China) Ltd For: Mar 11 | SEC filing · Form 6-K | SEC EDGAR | +0.14% | +1.32% | |
| Form 6-K HUTCHMED (China) Ltd For: Mar 09 | SEC filing · Form 6-K | SEC EDGAR | -0.15% | +0.73% | |
| HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China | Press release | GlobeNewswire | -0.15% | +0.73% | |
| Form 6-K HUTCHMED (China) Ltd For: Mar 06 | SEC filing · Form 6-K | SEC EDGAR | +1.09% | +1.09% | |
| Intended Retirement of Independent Non-executive Director and changes of composition of board committees | Press release | GlobeNewswire | +1.09% | +1.09% | |
| Form 20-F HUTCHMED (China) Ltd For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.51% | +1.09% | |
| Form 6-K HUTCHMED (China) Ltd For: Mar 05 | SEC filing · Form 6-K | SEC EDGAR | +0.51% | +1.09% | |
| HUTCHMED Reports 2025 Full Year Results and Business Updates | Press release | GlobeNewswire | +0.51% | +1.09% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the HCM section they belong to.
Where else HCM is measured.
HCM earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MiMedx Group, Inc (MDXG) | 265 | +0.14% | 57% |
| Relmada Therapeutics, Inc. (RLMD) | 265 | -0.01% | 44% |
| iBio, Inc. (IBIO) | 263 | -0.38% | 43% |
| NOVUS THERAPEUTICS (NVUS) | 263 | -0.14% | 40% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is HUTCHMED (China) Limited - American Depositary Shares's median reaction calculated?
Every labeled HCM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 263 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of HCM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does HCM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.